Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1453622 | 0.93 | CYP11B2 (0.41) | HTR1AHTR2AHTR7DRD3HTR2B | |
| SCHEMBL1454530 | 0.87 | ACHE (0.40) | HTR1AHTR2AHTR7DRD3HTR2B | |
| SCHEMBL1454044 | 0.85 | PTGS2 (0.33) | ACHEPTGS2CYP11B1CYP11B2DRD2 | |
| SCHEMBL1452435 | 0.84 | HTR1A (0.37) | HTR1AHTR2AHTR7DRD3HTR2B | |
| SCHEMBL1453738 | 0.83 | CYP11B2 (0.41) | HTR1AHTR2AHTR7DRD3HTR2B | |
| SCHEMBL1453680 | 0.78 | ACHE (0.37) | HTR1AHTR2AHTR7DRD3HTR2B | |
| SCHEMBL577446 | 0.78 | HTR1A (0.57) | HTR1AHTR2AHTR7DRD3HTR2B | |
| SCHEMBL1453699 | 0.77 | ACHE (0.36) | HTR1AHTR2AHTR7DRD3HTR2B | |
| SCHEMBL1453055 | 0.77 | PTGS2 (0.37) | HTR2ADRD3HTR2BACHEPTGS2 | |
| SCHEMBL1453837 | 0.76 | PTGS2 (0.33) | ACHEPTGS2CYP11B1CYP11B2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910783-B2 | Preparation of substituted bridged indenyl and related ligands | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20070135596-A1 | Preparation of substituted bridged indenyl and related ligands | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135596-A1 | Preparation of substituted bridged indenyl and related ligands | SP1, TTL, TTLL12 | HTR1A 3242/4885HTR2A 4085/4885HTR7 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.